In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out of CD3 in human T-cells. The goal is to improve T-cell-based immunotherapies to fight tumours using engineered allogenic T-cells from healthy donors. It is a very good example of how CRISPR-CAS9 can help medecine. And even if you are not very comfortable with CAR T-cells and the treatments of malignancies, I would recommend you read it and especially take a look at figure 2. Indeed, dear friends of genome editing, the authors made a clear and fair comparison of several KO strategies, covering all the main options. Thus, it is not only a major step for anti-tumour treatments but it is also an excellent overview that reveals the best approaches. So, before reading this post any further, you might like to read the article mentioned above. [Read more…]
CRISPR-Cas9 is a popular method that brings researchers endless experimental strategies to create their own research-based cellular models. In this post we’ll review a new transfection reagent especially engineered to maximize Cas9 vectors deliveries inside cells with low cellular toxicity.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas (CRISPR-associated) and Transcription Activator-Like Effector Nuclease (TALEN) are endonuclease based technologies aimed at developing targeted genome editing technologies.
CRISPR and TALEN provide Scientists with unique discovery tools for pathophysiology or genotype-phenotype studies by creating cellular models with gene knock-out, knock-in or tagging, promoter swapping, nucleotide substitution, protein truncation, reading frame disruption, modification of regulation by miRNA, genetic defect corrections…But, which one is the best for your application?
The CRISPR (Clustered, Regularly Interspaced, Short Palindromic Repeats)-Cas (CRISPR-associated) (CRISPR-Cas) system has become trendy as it is suitable for numerous applications such as gene knockouts, genome-engineering, to name but a few. In a recent Technical Bulletin, Ed Davis describes the mechanism of CRISPR-Cas for genome editing and how the recent experimental improvements improve CRISPR-Cas9 specificity while reducing off-target effects.